When was Gylden Pharma founded?

Gylden Pharma was founded in 2016.

Where is Gylden Pharma located?

Gylden Pharma is headquartered in Abingdon, United Kingdom.

Who is the current CEO of Gylden Pharma?

Thomas Rademacher and Thomas Rademacher s of Gylden Pharma. Thomas Rademacher has also founded 1 company.

Is Gylden Pharma a funded company?

Gylden Pharma is a funded company, having raised a total of $***** in its 1st and only funding round.

Where does Gylden Pharma rank among its competitors?

Gylden Pharma ranks 2866th amongst 2634 active competitors, of which 882 are funded. It stands 11th in terms of total funding among its competitors. The most recent competitor to raise funding was Erasca, which secured $45M in Mar, 2024.

Who are the top competitors of Gylden Pharma?

Gylden Pharma's top competitors include Jazz Pharmaceuticals, Sana Biotechnology and Juno Therapeutics. Among them, Erasca secured the most recent funding round in March, 2024.

Gylden Pharma - 2026 Company Profile, Team & Competitors

Gylden Pharma is an unfunded company based in Abingdon (United Kingdom), founded in 2016 by Storme Moore-Thornicroft, Thomas Rademacher, Storme Moore-Thornicroft, Thomas Rademacher and Laurens Rademacher. It operates as a Developer of T cell-priming vaccines and immunotherapies for infectious diseases. Gylden Pharma has not raised any funding yet. The company has 2634 active competitors, including 882 funded and 644 that have exited. Its top competitors include companies like Jazz Pharmaceuticals, Sana Biotechnology and Juno Therapeutics.

Company Details

Developer of T cell-priming vaccines and immunotherapies for infectious diseases. This company develops candidates for various infectious diseases, including betacoronaviruses, dengue fever, and influenza, as well as intracellular bacterial infections. Its core proprietary technologies are designed to elicit broad and long-lasting cellular immune responses. The company aims to positively impact global human health through the development of innovative T cell-priming product candidates addressing significant health threats. The vaccines and immunotherapies combine core proprietary technologies to achieve this goal.

Key Metrics

Founded Year

2016

Location

Abingdon, United Kingdom

Stage

Unfunded

Ranked

2866^th among 3243 competitors

Similar Companies

Bharat Biotech & 344 more

View Gylden Pharma's full profile

Gylden Pharma has not raised any funding rounds yet.

The founders of Gylden Pharma are Storme Moore-Thornicroft, Thomas Rademacher, Storme Moore-Thornicroft, Thomas Rademacher and Laurens Rademacher. Thomas Rademacher and Thomas Rademacher are the CEOs of Gylden Pharma.

Here are the details of Gylden Pharma's key team members:

Storme Moore-Thornicroft: Founder, Executive Director & COO of Gylden Pharma.
Thomas Rademacher: Founder and CEO of Gylden Pharma.
Storme Moore-Thornicroft: Founder, Executive Director, Chief Operating Officer of Gylden Pharma.
Thomas Rademacher: Founder and CEO of Gylden Pharma.
Laurens Rademacher: Co-founder and Chief Technology Officer of Gylden Pharma.

View details of Gylden Pharma's Founder profiles and Board Members

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Gylden Pharma include Jazz Pharmaceuticals, Sana Biotechnology and Juno Therapeutics. Here is the list of Top 10 competitors of Gylden Pharma, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Jazz Pharmaceuticals 2003, Dublin (Ireland), Public	Developer of novel biopharmaceutical medicines for unmet medical needs	$265M	Prospect Venture Partners, Versant Ventures ... & 14 others	82/100
2nd	Sana Biotechnology 2018, Seattle (United States), Public	Developer of genetically engineered cell therapies for multiple disorders	$821M	Omega Funds, Bezos Expeditions & 17 others	75/100
3rd	Juno Therapeutics 2013, Seattle (United States), Acquired	Global biopharmaceutical company discovering, developing, and delivering innovative medicines	$317M	Omega Funds, BB Biotech & 14 others	74/100
4th	C4 Therapeutics 2016, Cambridge (United States), Public	Developer of small molecule drugs for treating cancer	$223M	Cobro Ventures, Perceptive Advisors & 27 others	74/100
5th	Bharat Biotech 1996, Hyderabad (India), Early Stage	Manufacturer of vaccines and bio-therapeutic products	$13.7M	ICICI Venture, IFC & 25 others	72/100
6th	Blueprint Medicines 2008, Cambridge (United States), Acquired	Developer of selective kinase inhibitors for patients with genomically defined cancers	$115M	Third Rock Ventures, Nextech Invest & 20 others	72/100
7th	BioNTech 2008, Mainz (Germany), Public	Developer of immunotherapeutics for the treatment of cancer and other diseases	$861M	Redmile Group, Fidelity Investments & 28 others	72/100
8th	MacroGenics 2000, Rockville (United States), Public	Developer of novel biologics for the treatment of autoimmune disorders, cancer and infectious disease	$126M	Nextech Venture, Ventures West & 29 others	71/100
9th	iTeos Therapeutics 2011, Cambridge (United States), Acquired	Developer of immunotherapy for treating cancer	$204M	Boxer Capital, RA Capital Management & 19 others	70/100
10th	Erasca 2018, San Diego (United States), Public	Developer of small molecule based therapeutics for cancer	$300M	Arch Venture Partners, Cormorant Asset Management ... & 13 others	70/100
2866th	Gylden Pharma 2016, Abingdon (United Kingdom), Unfunded	Developer of T cell-priming vaccines and immunotherapies for infectious diseases	-	-	16/100